Cue Biopharma (CUE) EBIT (2017 - 2026)
Cue Biopharma's (CUE) quarterly EBIT came in at -$87.7 million in Q2 2026, down 915.58% year-over-year from $10.8 million in Q2 2025, and down 4533.52% quarter-over-quarter from $2.0 million in Q4 2025.
Powered by 
Analysis
Cue Biopharma (CUE) EBIT (2017 - 2026) Analysis & Trends
Cue Biopharma has disclosed EBIT across 10 years of filings, most recently posting -$87.7 million for Q2 2026.
- In Q2 2026, EBIT fell 915.58% year-over-year to -$87.7 million; the TTM figure through Jun 2026 stood at -$101.9 million (down 158.87% YoY), while the FY2025 annual figure was -$26.6 million, up 36.02% from the prior year.
- EBIT came in at -$87.7 million for Q2 2026 at Cue Biopharma, down from $2.0 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $2.0 million in Q4 2025 to a low of -$87.7 million in Q2 2026.
- Average EBIT over 5 years is -$15.4 million, with a median of -$12.3 million recorded in 2025.
- Year-over-year, EBIT soared 120.53% in 2025 and tumbled 915.58% in 2026.
- Over 5 years, EBIT stood at -$14.9 million in 2022, then increased by 6.96% to -$13.8 million in 2023, then jumped by 30.36% to -$9.6 million in 2024, then soared by 120.53% to $2.0 million in 2025, then plunged by 4533.52% to -$87.7 million in 2026.
- Per Business Quant data, the three most recent EBIT figures were -$87.7 million in Q2 2026, $2.0 million in Q4 2025, and -$7.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -365.99 Mn |
| 10 | Cue Biopharma | 179.95 Mn | 162.53 Mn | - | -87.70 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -87.70 Mn |
| Dec 31, 2025 | 1.98 Mn |
| Sep 30, 2025 | -7.60 Mn |
| Jun 30, 2025 | -8.64 Mn |
| Mar 31, 2025 | -12.30 Mn |
| Dec 31, 2024 | -9.63 Mn |
| Sep 30, 2024 | -8.82 Mn |
| Jun 30, 2024 | -10.38 Mn |
| Mar 31, 2024 | -12.67 Mn |
| Dec 31, 2023 | -13.83 Mn |
| Sep 30, 2023 | -11.42 Mn |
| Jun 30, 2023 | -13.52 Mn |
| Mar 31, 2023 | -13.38 Mn |
| Dec 31, 2022 | -14.87 Mn |
| Sep 30, 2022 | -11.03 Mn |
| Jun 30, 2022 | -13.09 Mn |
| Mar 31, 2022 | -14.24 Mn |
| Dec 31, 2021 | -7.89 Mn |
| Sep 30, 2021 | -13.02 Mn |
| Jun 30, 2021 | -10.30 Mn |